Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.

Farber RS, Sand IK.

Ther Adv Neurol Disord. 2015 Sep;8(5):212-32. doi: 10.1177/1756285615598910. Review.

2.

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.

Thamilarasan M, Hecker M, Goertsches RH, Paap BK, Schröder I, Koczan D, Thiesen HJ, Zettl UK.

J Neuroinflammation. 2013 Oct 17;10:126. doi: 10.1186/1742-2094-10-126.

3.

Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Jalilian B, Einarsson HB, Vorup-Jensen T.

Int J Mol Sci. 2012 Nov 9;13(11):14579-605. doi: 10.3390/ijms131114579. Review.

4.

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Boster A, Bartoszek MP, O'Connell C, Pitt D, Racke M.

Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108.

5.

Glatiramer acetate in the treatment of multiple sclerosis.

Tselis A, Khan O, Lisak RP.

Neuropsychiatr Dis Treat. 2007 Apr;3(2):259-67.

6.

Glatiramer in the treatment of multiple sclerosis.

Rizvi SA, Kim E, Moodie J.

Int J Nanomedicine. 2006;1(3):283-9. Review.

Supplemental Content

Support Center